Anbio Biotechnology (NNNN) Change in Accured Expenses (2024 - 2025)
Anbio Biotechnology (NNNN) recorded quarterly Change in Accured Expenses of $70.8 billion in Q2 2025, down 32.58% quarter-over-quarter from $105.0 billion in Q4 2024.
Anbio Biotechnology (NNNN) Change in Accured Expenses (2024 - 2025) Analysis & Trends
Anbio Biotechnology's Change in Accured Expenses history runs 2 years deep, the most recent figure standing at $70.8 billion for Q2 2025.
- In Q2 2025, Change in Accured Expenses changed N/A year-over-year to $70.8 billion; the TTM figure through Jun 2025 stood at $70.8 billion (changed N/A YoY), while the FY2025 annual figure was -$17143.0, down 100.0% from the prior year.
- Change in Accured Expenses was $70.8 billion for Q2 2025 at Anbio Biotechnology, down from $105.0 billion in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $105.0 billion in Q4 2024 to a low of $70.8 billion in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Accured Exp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 148.09 Bn | 143.69 Bn | 1.83 Bn | -284.70 Mn |
| 2 | Becton Dickinson | 41.00 Bn | 39.99 Bn | 2.15 Bn | - |
| 3 | Medline | 30.38 Bn | 36.22 Bn | 1.84 Bn | -32.00 Mn |
| 4 | Resmed | 28.22 Bn | 26.56 Bn | 890.98 Mn | 103.88 Mn |
| 5 | West Pharmaceutical Services | 23.72 Bn | 23.19 Bn | 296.40 Mn | - |
| 6 | Solventum | 13.33 Bn | 13.33 Bn | 1.10 Bn | -151.00 Mn |
| 7 | Cooper Companies | 13.12 Bn | 12.99 Bn | 735.40 Mn | - |
| 8 | Align Technology | 12.86 Bn | 11.80 Bn | 736.59 Mn | 5.38 Mn |
| 9 | Baxter International | 10.51 Bn | 8.47 Bn | 891.00 Mn | 203.00 Mn |
| 10 | Anbio Biotechnology | 720.59 Mn | 708.69 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 70.78 Bn |
| Jun 30, 2025 | 70.78 Bn |
| Dec 31, 2024 | 104.98 Bn |
| Dec 31, 2024 | 104.98 Bn |